Glycorex Transplantation AB (publ)
Glycorex Transplantation AB (publ), a medical technology company, focuses on transplantation, blood transfusion, and autoimmune diseases. It develops an antigen-specific immunoadsorption to reduce blood group antibodies and autoantibodies in the blood. The company's principal product is Glycosorb-ABO, which enables blood group incompatible kidney transplantation and is also used to enable heart, … Read more
Glycorex Transplantation AB (publ) (O33) - Total Assets
Latest total assets as of September 2025: €53.52 Million EUR
Based on the latest financial reports, Glycorex Transplantation AB (publ) (O33) holds total assets worth €53.52 Million EUR as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Glycorex Transplantation AB (publ) - Total Assets Trend (2021–2024)
This chart illustrates how Glycorex Transplantation AB (publ)’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Glycorex Transplantation AB (publ) - Asset Composition Analysis
Current Asset Composition (December 2024)
Glycorex Transplantation AB (publ)'s total assets of €53.52 Million consist of 36.8% current assets and 63.2% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 11.5% |
| Accounts Receivable | €7.01 Million | 13.9% |
| Inventory | €4.73 Million | 9.4% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how Glycorex Transplantation AB (publ)'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Glycorex Transplantation AB (publ)'s current assets represent 36.8% of total assets in 2024, a decrease from 49.7% in 2021.
- Cash Position: Cash and equivalents constituted 11.5% of total assets in 2024, down from 40.5% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 39.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 13.9% of total assets.
Glycorex Transplantation AB (publ) Competitors by Total Assets
Key competitors of Glycorex Transplantation AB (publ) based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Glycorex Transplantation AB (publ) - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Glycorex Transplantation AB (publ) generates 0.70x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Glycorex Transplantation AB (publ) is currently not profitable relative to its asset base.
Glycorex Transplantation AB (publ) - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.93 | 1.39 | 1.39 |
| Quick Ratio | 1.56 | 1.01 | 1.01 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €11.75 Million | € 5.56 Million | € 5.56 Million |
Glycorex Transplantation AB (publ) - Advanced Valuation Insights
This section examines the relationship between Glycorex Transplantation AB (publ)'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.12 |
| Asset Growth Rate (YoY) | -23.6% |
| Total Assets | €50.30 Million |
| Market Capitalization | $5.95 Million USD |
Valuation Analysis
Below Book Valuation: The market values Glycorex Transplantation AB (publ)'s assets below their book value (0.12 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Glycorex Transplantation AB (publ)'s assets decreased by 23.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Glycorex Transplantation AB (publ) (2021–2024)
The table below shows the annual total assets of Glycorex Transplantation AB (publ) from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €50.30 Million | -23.60% |
| 2023-12-31 | €65.84 Million | -31.47% |
| 2022-12-31 | €96.08 Million | -5.62% |
| 2021-12-31 | €101.80 Million | -- |